Clinical Trial Update: Chemoradiation and Panitumumab for Esophageal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating chemoradiation combined with panitumumab for esophageal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Adenocarcinoma
• Esophageal Cancer
• Esophageal Squamous Cell Carcinoma
• Gastro-esophageal Junction Cancer

Drugs mentioned

• Panitumumab (panitumumab)

Snippet

Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Conditions: Squamous Cell Carcinoma, Adenocarcinoma | Phase 2 | Status: COMPLETED